Drugs in development for toxoplasmosis: advances, challenges, and current status

• Main Authors: Alday PH, Doggett JS
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-01-01
• Series: Drug Design, Development and Therapy
• Subjects: Toxoplasma gondii; therapeutics; preclinical medicine; experimental medicine; mechanism of action; Apicomplexa
• Online Access: https://www.dovepress.com/drugs-in-development-for-toxoplasmosis-advances-challenges-and-current-peer-reviewed-article-DDDT

P Holland Alday,1 Joseph Stone Doggett1,2 1Division of Infectious Diseases, Oregon Health & Science University, 2Portland Veterans Affairs Medical Center, Portland, OR, USA Abstract: Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T. gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis. Keywords: Toxoplasma gondii, therapeutics, preclinical medicine, experimental medicine, mechanism of action, Apicomplexa